Table 3: Compare the mean of NCV in treated patients with topiramate by type of nerves.

 Type of nerves

Drugs

Mean

P - value

Median

topiramate in baseline

52.3

0.003

 

Control

58.7

Median

topiramate in baseline

52.3

0.053

 

topiramate six month late

52.4

Ulnar

topiramate in baseline

50.2

0.0024

 

Control

50.8

Ulnar

topiramate in baseline

50.2

0.061

 

topiramate six month late

50.1

Sural

topiramate in Baseline

46.7

0.003

 

Control

50.6

Sural

topiramate in baseline

46.7

0.298

 

topiramate six month late

46.2

Peroneal

topiramate in baseline

43.8

0.0051

 

Control

46.4

Peroneal

topiramate in baseline

43.8

0.13

topiramate six month late

43.02